About Catalym
CatalYm is targeting GDF-15, a cancer resistance mechanism, with its lead antibody, Visugromab. This therapy has shown durable anti-tumor efficacy in relapsed metastatic solid tumors when combined with anti-PD-1. CatalYm is now moving into Phase 2b trials to establish Visugromab as a new class of cancer immunotherapy across various treatments.
Legal Name
: Catalym
Headquarters
: Bayern , Germany
Business Model
: B2C
Founding Date
: 1970
No. of Employees
: 11-20
Founding Members
: 1. Jörg Wischhusen PhD CEO
Revenue Stream
Fee-For-ServiceRecently Added Startups
Rayscape
Rayscape mission is to help radiologists by giving them smart AI tools that make it easier to analyze medical images and give more accurate diagnoses.
Evolvo
Evolve is changing the vacation rental experience with a modern way of managing properties and taking care of guests.
Suvoda
Suvoda is a global company that provides technology for clinical trials, helping support complex studies for important, life-saving treatments.
Related Post
CatalYm funding news – Munich-based CatalYm Secures $150 Million in Series D Round Funding
Top 12 HealthTech Startups in Germany
Startups Hit €125 million+ in 2024 Funding Report
